RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsBreast cancer heterogeneity determines cancer progression, treatment effects, and prognosis.
The heterogeneity of breast cancer is attributed to differences in the genomic, epigenomic, transcriptomic, and proteomic characteristics of the cancer cells. These factors affect tumor properties such as proliferation, apoptosis, metastasis, and therapeutic response. This heterogeneity is also observed in tumor tissues among different patients or different metastases (intertumor heterogeneity) and within the individual tumor from the same patient (intratumor heterogeneity)
Breast cancer heterogeneity increases the difficulty of early diagnosis, treatment selection, and prognosis prediction.
The TME plays a significant role in tumor growth and metastasis and has always been an important obstacle during tumor therapy. The TME has many heterogeneous cell populations, including fibroblasts, adipocytes, immune cells, epithelial cells, pericytes, and extracellular matrix components. Interactions between tumor cells and their microenvironment contribute to tumor heterogeneity, thus promoting tumor progression.
ONCYs pelareorep as demonstrated its ability to remodel and prime the TME in advance of CPI administration, leading to the ability to address tumor heterogeneity expressed in breast cancers, in particular hr-positive (her2- negative) breast cancer
https://ehoonline.biomedcentral.com/articles/10.1186/s40164-022-00363-1